Outcomes following pancreatic surgery using three different thromboprophylaxis regimens. BJS 2019; 106: 765-773.
Published: 18th February 2019
Authors: R. G. Hanna‐Sawires, J. V. Groen, F. A. Klok, R. A. E. M. Tollenaar, W. E. Mesker, R. J. Swijnenburg et al.
Postpancreatectomy haemorrhage (PPH) and venous thromboembolism (VTE) are serious complications following pancreatic surgery. The aim was to assess the timing, occurrence and predictors of PPH and VTE.
Elective pancreatic resections undertaken in a single university hospital between November 2013 and September 2017 were assessed. Three intervals were reviewed, each with a different routine regimen of nadroparin: 2850 units once daily (single dose) administered in hospital only, or 5700 units once daily (double dose) or 2850 units twice daily (split dose) administered in hospital and continued for 6 weeks after surgery. Clinically relevant PPH (CR‐PPH) was classified according to International Study Group of Pancreatic Surgery criteria. VTE was defined according to a number of key diagnostic criteria within 6 weeks of surgery. Cox regression analyses were performed to test the hypotheses that the double‐dose group would experience more PPH than the other two groups, the single‐dose group would experience more VTE than the other two groups, and the split‐dose group would experience the fewest adverse events (PPH or VTE).
In total, 240 patients were included, 80 per group. The double‐dose group experienced significantly more CR‐PPH (hazard ratio (HR) 2·14, 95 per cent c.i. 1·16 to 3·94; P = 0·015). More relaparotomies due to CR‐PPH were performed in the double‐dose group (16 versus 3·8 per cent; P = 0·002). The single‐dose group did not experience more VTE (HR 1·41, 0·43 to 4·62; P = 0·570). The split dose was not associated with fewer adverse events (HR 0·77, 0·41 to 1·46; P = 0·422). Double‐dose low molecular weight heparin (LMWH), high BMI and pancreatic fistula were independent predictors of CR‐PPH.
A double dose of LMWH prophylaxis continued for 6 weeks after pancreatic resection was associated with a twofold higher rate of CR‐PPH, resulting in four times more relaparotomies. Patients receiving a single daily dose of LMWH in hospital only did not experience a higher rate of VTE.Full text
You may also be interested in
Authors: A. Pulvirenti, A. Pea, N. Rezaee, C. Gasparini, G. Malleo, M. J. Weiss et al.
Impact of postoperative infective complications on long‐term survival after liver resection for hepatocellular carcinoma.
Authors: T. Yang, K. Liu, C.‐F. Liu, Q. Zhong, J. Zhang, J.‐J. Yu et al.
Meta‐analysis of randomized clinical trials of early versus delayed cholecystectomy for mild gallstone pancreatitis.
Authors: N. Moody, A. Adiamah, F. Yanni, D. Gomez
Authors: L. Lundgren, C. Muszynska, A. Ros, G. Persson, O. Gimm, B. Andersson et al.
Meta‐analysis of effect of routine enteral nutrition on postoperative outcomes after pancreatoduodenectomy.
Authors: M. Tanaka, M. Heckler, A. L. Mihaljevic, P. Probst, U. Klaiber, U. Heger et al.
Management of isolated recurrence after surgery for pancreatic adenocarcinoma. BJS 2019; 106: 898-909.
Authors: Y. I. Kim, K. B. Song, Y.‐J. Lee, K.‐M. Park, D. W. Hwang, J. H. Lee et al.
Costs and quality of life in a randomized trial comparing minimally invasive and open distal pancreatectomy (LEOPARD trial). BJS 2019; 106: 910-921.
Authors: J. van Hilst, E. A. Strating, T. de Rooij, F. Daams, S. Festen, B. Groot Koerkamp et al.
Hepatectomy for hepatocellular carcinoma after perioperative management of portal hypertension. BJS 2019; 106: 1066-1074.
Authors: N. Takemura, T. Aoki, K. Hasegawa, J. Kaneko, J. Arita, N. Akamatsu et al.
Clinical value of additional resection of a margin‐positive distal bile duct in perihilar cholangiocarcinoma. BJS 2019; 106: 774-782.
Authors: S. Otsuka, T. Ebata, Y. Yokoyama, T. Mizuno, T. Tsukahara, Y. Shimoyama et al.
Impact of resection margin status on recurrence and survival in pancreatic cancer surgery. BJS 2019; 106: 1055-1065.
Authors: W. S. Tummers, J. V. Groen, B. G. Sibinga Mulder, A. Farina‐Sarasqueta, J. Morreau, H. Putter et al.
Multicentre study of multidisciplinary team assessment of pancreatic cancer resectability and treatment allocation. BJS 2019; 106: 756-764.
Authors: J. Kirkegård, E. K. Aahlin, M. Al‐Saiddi, S. O. Bratlie, M. Coolsen, R. J. de Haas et al.
Major hepatectomy with or without pancreatoduodenectomy for advanced gallbladder cancer. BJS 2019; 106: 626-635.
Authors: T. Mizuno, T. Ebata, Y. Yokoyama, T. Igami, J. Yamaguchi, S. Onoe et al.